Abstract No. 542 Survival analysis of 79 patients with advanced hepatocellular carcinoma treated with Y90

Abstract

We present the survival data of nine year experience of Y90 treatments for advanced HCC performed at Detroit Medical Center. Retrospective survival analysis of all patients treated with Y90 TherasPhere for advanced HCC was done from 2008 to 2016 at Detroit Medical Center. Out of 96 patients 79 had data available for the overall survival calculated from the date of the treatment to the date of death or present date. The data analysis was performed with SPSS package using survival analysis with Kaplan-Meier and Log rank tools. Survival data was obtained from 79 patients with HCC undergoing treatment with Y90 therasphere embolization. The median survival was estimated to be 330 days with a standard error of 41.8 (95%CI: 248.1-411.9). Two patients expired within 30 days of treatment, which by definition was considered to be treatment related mortality. 60 (75.9%) were male and 19 (24.1%) were female. The mean age of the patients at diagnosis was 63.8 ± 9.0 years. The mean tumor burden was 28.5% with a standard deviation of 20.1. History of Sorafenib chemotherapy did not significantly affect the survival outcomes. Out of 79 patients, 20 (25.3%) had a history of Sorafenib chemotherapy with a median survival of 306.0 ± 168.4 days. Patients that did not have a history of Sorafenib chemotherapy demonstrated a median survival of 330.0 ± 61.6 days (p = 0.640). Barcelona scores were available for 79 patients; 23 were stage B, 54 were stage C, and 2 were stage D. The median survival was 494.0 ± 190.4 days (95%CI:120.8-867.2) for Barcelona stage B patients and 293.0 ± 38.4 days (95%CI:217.8-368.2) for Barcelona stage C patients. One of the stage D patients died 92 days after the treatment and the other one was alive at the time of the analysis. Our survival results after Y90 TherasPhere are comparable to the previously reported data and confirm the survival benefit of Y90 in non resectable HCC patients.